Is it all in the genes? HLA risk for celiac disease in a Down syndrome cohort

Stahl Marisa G1, Shaw Jessica R2, Rachubinski Angela L2, Galbraith Matthew D2, Sokol Ronald J1, Norman Paul3, Sameer Chavan3, Leaton Laura A3, Liu Edwin1 & Espinosa Joaquin2

1Pediatric Gastroenterology, Hepatology, and Nutrition, University of Colorado School of Medicine, Children’s Hospital Colorado, Aurora, CO 2Linda Cnric Institute for Down Syndrome, University of Colorado, Aurora, CO 3Division of Biomedical Informatics and Personalized Medicine, Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

BACKGROUND

• Individuals with Down syndrome (T21) have a six-fold greater risk of celiac disease (CD).1
• Although alone not sufficient, CD development requires most commonly, human leukocyte antigen (HLA) DQ2.5 or DQ8.1 and less commonly DQ2.2 or DQ7.5 in the typical population.2
• While the mechanism of increased risk for celiac in T21 remains to be elucidated, previous studies suggest those with T21 may have differing HLA risks than the typical population.3,4

OBJECTIVES/AIMS

• To examine and compare the genetic risk profiles of those with T21 in the Human Trisome Project (HTP) with and without a diagnosis of CD.
• To compare the genetic risk profiles of those with T21 and CD to published genetic risk profiles for CD in the typical population.
• To examine whether a published genetic risk score for CD in the typical population2 can predict CD in individuals with T21.

DESIGN/METHODS

• Genomic data and celiac status were available for 210 individuals with T21 from the Human Trisome Project (HTP).
• Celiac diagnosis was ascertained from participant surveys and medical records.
• Genotyping was performed using the Illumina Multi-Ethnic Global Array (MEGA).
• HLA genotype imputation was performed using the HIBAG algorithm.5
• Celiac-permissive HLA genotype frequencies were compared in celiac cases and controls with T21.
• HLA genotype frequencies among CD cases and controls with T21 were compared against published frequencies in the typical population.2
• Imputed HLA genotypes and 32 of 38 available non-HLA SNPs were used to approximate a celiac genetic risk score (GRS) developed for the typical population.2
• The modified GRS was evaluated for its ability to predict CD in HTP participants with T21.

RESULTS

Table 1 Demographic data

<table>
<thead>
<tr>
<th></th>
<th>Non-Hispanic white</th>
<th>Female</th>
<th>Age (Mean (SD))</th>
</tr>
</thead>
<tbody>
<tr>
<td>T21 without celiac</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(N = 191)</td>
<td>77</td>
<td>46.6</td>
<td>24.6 (12.1)</td>
</tr>
<tr>
<td>T21 with celiac</td>
<td>84.2</td>
<td>36.8</td>
<td>25.3 (9.5)</td>
</tr>
</tbody>
</table>

Figure 1 HLA-DQ genotype frequencies among celiac cases and controls with Down syndrome (T21) and without (D21)

- 95% of T21 participants with CD vs. 71% of participants with T21 without CD had permissive HLA genotypes.
- 5% of T21 participants with CD did not carry a traditionally celiac permissive HLA genotype.
- No T21 participants with CD were DQ2.5 homozygous.
- Participants with T21 and CD most frequently had the following genotypes: DQ2.5/X (21.1%) DQ2.2/X (21.1%).

Figure 2 Performance of celiac GRS in individuals with T21

- Traditionally non-permissive genotypes including DOX/X and DQ7.5/X were observed with higher frequency in the DS population with celiac disease compared to the typical population.

REFERENCE


CONCLUSIONS

While a majority of the participants with T21 and CD had the typical high-risk HLA genotypes, the other genotypes typically considered to be low risk (yet still permissive) appear to contribute more to celiac disease in those with T21 compared to the general population.

In clinical practice, this means that HLA testing may not be as useful to rule out celiac disease in the T21 population.

Further multicenter genomic studies are being planned to look at the HLA risk in a larger sample size and the non-HLA contributions.

The authors have no conflict of interest to report. This work is funded by NIH grant KL2TR002534-03S1.